Qianyuan Pharmaceutical announced that its subsidiary Jiangsu Jiayi Pharmaceutical Co., Ltd. received the "Notice of Approval of the Application for Marketing of Chemical APIs" for Ebastine issued by the State Drug Administration. Ebastine is suitable for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria with or without allergic conjunctivitis. The original developer of Ebastine is INDUSTRIAS FARMACEUTICAS ALMIRALL, SA. The Ebastine tablets of its subsidiary Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. have passed the consistency evaluation and have been included in the Class B National Medical Insurance Catalog. After the Ebastine API is approved for marketing, it will further reduce the production cost of the preparation products and enhance the market competitiveness of the products.